Ken Griffin Belite Bio, Inc Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Belite Bio, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 5,211 shares of BLTE stock, worth $352,941. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,211
Previous 6,460
19.33%
Holding current value
$352,941
Previous $302,000
8.61%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BLTE
# of Institutions
22Shares Held
280KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY168KShares$11.4 Million0.15% of portfolio
-
State Street Corp Boston, MA20KShares$1.36 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC18.3KShares$1.24 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY14.6KShares$991,2960.0% of portfolio
-
Ubs Group Ag12.2KShares$826,7800.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.68B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...